Hironori Ishigami

2.8k total citations · 1 hit paper
85 papers, 2.1k citations indexed

About

Hironori Ishigami is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Gastroenterology. According to data from OpenAlex, Hironori Ishigami has authored 85 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Surgery, 52 papers in Pulmonary and Respiratory Medicine and 33 papers in Gastroenterology. Recurrent topics in Hironori Ishigami's work include Intraperitoneal and Appendiceal Malignancies (46 papers), Gastric Cancer Management and Outcomes (43 papers) and Gastrointestinal Tumor Research and Treatment (32 papers). Hironori Ishigami is often cited by papers focused on Intraperitoneal and Appendiceal Malignancies (46 papers), Gastric Cancer Management and Outcomes (43 papers) and Gastrointestinal Tumor Research and Treatment (32 papers). Hironori Ishigami collaborates with scholars based in Japan, Switzerland and United States. Hironori Ishigami's co-authors include Hironori Yamaguchi, Hiroharu Yamashita, Joji Kitayama, Joji Kitayama, Shigenobu Emoto, Shoichi Kaisaki, Hirokazu Nagawa, Toshiaki Watanabe, Daisuke Soma and Takao Kamei and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Hironori Ishigami

81 papers receiving 2.0k citations

Hit Papers

Phase III Trial Comparing Intraperitoneal and Intravenous... 2018 2026 2020 2023 2018 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial
    2018 250 citations Hironori Ishigami, Yoshiyuki Fujiwara et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hironori Ishigami Japan 24 1.2k 1.0k 504 485 317 85 2.1k
Kanji Katayama Japan 25 1.0k 0.8× 467 0.5× 194 0.4× 510 1.1× 440 1.4× 128 2.1k
Yoshiaki Kuriu Japan 25 1.1k 0.9× 1.0k 1.0× 213 0.4× 827 1.7× 32 0.1× 210 2.4k
C Sakakura Japan 17 363 0.3× 308 0.3× 124 0.2× 267 0.6× 83 0.3× 28 983
Ming‐Yan Cai China 30 2.1k 1.7× 971 1.0× 2.0k 3.9× 216 0.4× 22 0.1× 121 2.8k
Bernadette Liegl‐Atzwanger Austria 25 528 0.4× 1.3k 1.3× 372 0.7× 863 1.8× 31 0.1× 109 2.2k
Daniel A. Rushing United States 20 283 0.2× 771 0.8× 286 0.6× 564 1.2× 24 0.1× 42 1.5k
Hyuk-Joon Lee South Korea 26 997 0.8× 1.4k 1.4× 785 1.6× 398 0.8× 14 0.0× 83 2.6k
Shashikant Lele United States 16 1.3k 1.0× 319 0.3× 41 0.1× 560 1.2× 1.6k 5.0× 29 2.5k
Yasutoshi Murayama Japan 22 616 0.5× 876 0.9× 132 0.3× 513 1.1× 17 0.1× 158 1.6k
Zhi Peng China 26 434 0.3× 669 0.7× 146 0.3× 1.3k 2.7× 26 0.1× 106 2.1k

Countries citing papers authored by Hironori Ishigami

Since Specialization
Citations

This map shows the geographic impact of Hironori Ishigami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hironori Ishigami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hironori Ishigami more than expected).

Fields of papers citing papers by Hironori Ishigami

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hironori Ishigami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hironori Ishigami. The network helps show where Hironori Ishigami may publish in the future.

Co-authorship network of co-authors of Hironori Ishigami

This figure shows the co-authorship network connecting the top 25 collaborators of Hironori Ishigami. A scholar is included among the top collaborators of Hironori Ishigami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hironori Ishigami. Hironori Ishigami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cortés‐Guiral, Delia, Olivia Sgarbură, Mohammad Alyami, et al.. (2021). Priorities, actions and risks in the COVID-19 pandemic: a flash SoMe survey among surgical oncologists. PubMed. 6(1). 7–12. 1 indexed citations
2.
Kitayama, Joji, Hironori Ishigami, Hironori Yamaguchi, et al.. (2017). Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model. PubMed. 2(2). 95–102. 5 indexed citations
3.
Aizawa, Masaki, Hironori Ishigami, Hiroshi Yabusaki, et al.. (2017). Phase II study of intraperitoneal paclitaxel plus S-1/paclitaxel for gastric cancer with positive peritoneal cytology: CY-PHOENIX trial.. Journal of Clinical Oncology. 35(4_suppl). 96–96. 8 indexed citations
4.
Ishigami, Hironori, Yoshiyuki Fujiwara, Ryoji Fukushima, et al.. (2016). Phase III study of intraperitoneal paclitaxel plus s-1/paclitaxel compared with s-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial.. Journal of Clinical Oncology. 34(15_suppl). 4014–4014. 11 indexed citations
5.
Takahara, Naminatsu, Hiroyuki Isayama, Yousuke Nakai, et al.. (2016). Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Investigational New Drugs. 34(5). 636–642. 30 indexed citations
6.
Fujiwara, Yoshiyuki, Hironori Ishigami, Hiroto Miwa, et al.. (2016). Phase II study of intraperitoneal paclitaxel plus S-1/oxaliplatin for gastric cancer with peritoneal metastasis: SOX+IP PTX trial.. Journal of Clinical Oncology. 34(15_suppl). 4040–4040. 74 indexed citations
7.
Yamaguchi, Hironori, Joji Kitayama, Hironori Ishigami, et al.. (2016). A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report. Journal of Medical Case Reports. 10(1). 14–14. 3 indexed citations
8.
9.
Kitayama, Joji, Shigenobu Emoto, Hironori Yamaguchi, et al.. (2014). CD90(+)CD45(−) intraperitoneal mesothelial-like cells inhibit T cell activation by production of arginase I. Cellular Immunology. 288(1-2). 8–14. 14 indexed citations
10.
Kitayama, Joji, Shigenobu Emoto, Hironori Yamaguchi, Hironori Ishigami, & Toshiaki Watanabe. (2014). Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels. Cancer Chemotherapy and Pharmacology. 73(3). 605–612. 7 indexed citations
11.
Emoto, Shigenobu, Joji Kitayama, Hironori Ishigami, Hironori Yamaguchi, & Toshiaki Watanabe. (2014). Clinical Significance of Cytological Status of Peritoneal Lavage Fluid During Intraperitoneal Chemotherapy for Gastric Cancer with Overt Peritoneal Dissemination. Annals of Surgical Oncology. 22(3). 780–786. 10 indexed citations
12.
Kitayama, Joji, Shigenobu Emoto, Hironori Yamaguchi, Hironori Ishigami, & Toshiaki Watanabe. (2014). CD90(+) Mesothelial-Like Cells in Peritoneal Fluid Promote Peritoneal Metastasis by Forming a Tumor Permissive Microenvironment. PLoS ONE. 9(1). e86516–e86516. 20 indexed citations
13.
Kitayama, Joji, Shigenobu Emoto, Hironori Yamaguchi, et al.. (2013). Flow cytometric quantification of intraperitoneal free tumor cells in patients with peritoneal metastasis. Cytometry Part B Clinical Cytometry. 86(1). 56–62. 13 indexed citations
14.
Kitayama, Joji, Hironori Ishigami, Hironori Yamaguchi, Shigenobu Emoto, & Toshiaki Watanabe. (2013). Gastrectomy after intravenous and intraperitoneal paclitaxel combined with oral S-1 for gastric cancer with peritoneal metastasis.. Journal of Clinical Oncology. 31(4_suppl). 96–96.
15.
Emoto, Shigenobu, Hironori Ishigami, Hiroharu Yamashita, et al.. (2011). Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 15(2). 154–161. 118 indexed citations
16.
Kitayama, Joji, Hironori Ishigami, Shoichi Kaisaki, et al.. (2010). Weekly Intravenous and Intraperitoneal Paclitaxel Combined with S-1 for Malignant Ascites due to Advanced Gastric Cancer. Oncology. 78(1). 40–46. 17 indexed citations
17.
Ishigami, Hironori, Joji Kitayama, Shoichi Kaisaki, et al.. (2009). Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Annals of Oncology. 21(1). 67–70. 183 indexed citations
18.
Yamada, Jun, Joji Kitayama, Nelson H. Tsuno, et al.. (2008). Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle – A new strategy against peritoneal dissemination of gastric cancer. Cancer Letters. 272(2). 307–315. 13 indexed citations
19.
20.
Hashimoto, Takuya, Joji Kitayama, Akio Hidemura, et al.. (2007). Ume (Japanese Apricot)-Induced Small Bowel Obstruction with Chronic Radiation Enteritis. Case Reports in Gastroenterology. 1(1). 184–189. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kanji Katayama Breakdown of academic impact, for papers by Yoshiaki Kuriu Breakdown of academic impact, for papers by C Sakakura Breakdown of academic impact, for papers by Ming‐Yan Cai Breakdown of academic impact, for papers by Bernadette Liegl‐Atzwanger Breakdown of academic impact, for papers by Daniel A. Rushing Breakdown of academic impact, for papers by Hyuk-Joon Lee Breakdown of academic impact, for papers by Shashikant Lele Breakdown of academic impact, for papers by Yasutoshi Murayama Breakdown of academic impact, for papers by Zhi Peng
Rankless by CCL
2026